The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Impact of Prophylactic Immediate Posttransplant Ganciclovir on Development of Transplant Atherosclerosis: A Post Hoc Analysis of a Randomized, Placebo-Controlled Study
Open accessAbstract
Background —Coronary artery disease occurs in an accelerated fashion in the donor heart after heart transplantation (TxCAD), but the cause is poorly understood. The risk of developing TxCAD is increased by cytomegalovirus (CMV) infection and decreased by use of calcium blockers. Our group observed that prophylactic administration of ganciclovir early after heart transplantation inhibited CMV illness, and we now propose to determine whether this therapy also prevents TxCAD. Methods and Results —One hundred forty-nine consecutive patients (131 men and 18 women aged 48±13 years) were randomized to receive either ganciclovir or placebo during the initial 28 days after heart transplantation. Immunosuppression consisted of muromonab-CD3 (OKT-3) prophylaxis and maintenance with cyclosporine, prednisone, and azathioprine. Mean follow-up time was 4.7±1.3 years. In a post hoc analysis of this trial designed to assess efficacy of ganciclovir for prevention of CMV disease, we compared the actuarial incidence of TxCAD, defined by annual angiography as the presence of any stenosis. Because calcium blockers have been shown to prevent TxCAD, we analyzed the results by stratifying patients according to use of calcium blockers. TxCAD could not be evaluated in 28 patients because of early death or limited follow-up. Among the evaluable patients, actuarial incidence of TxCAD at follow-up (mean, 4.7 years) in ganciclovir-treated patients (n=62) compared with placebo (n=59) was 43±8% versus 60±10% ( P <0.1). By Cox multivariate analysis, independent predictors of TxCAD were donor age >40 years (relative risk, 2.7; CI, 1.3 to 5.5; P <0.01) and no ganciclovir (relative risk, 2.1; CI, 1.1 to 5.3; P =0.04). Stratification on the basis of calcium blocker use revealed differences in TxCAD incidence when ganciclovir and placebo were compared: no calcium blockers (n=53), 32±11% (n=28) for ganciclovir versus 62±16% (n=25) for placebo ( P <0.03); calcium blockers (n=68), 50±14% (n=33) for ganciclovir versus 45±12% (n=35) for placebo ( P =NS). Conclusions —TxCAD incidence appears to be lower in patients treated with ganciclovir who are not treated with calcium blockers. Given the limitations imposed by post hoc analysis, a randomized clinical trial is required to address this issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pravastatin on outcomes after cardiac transplantation
Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301
Cytomegalovirus Infection Is Associated With Cardiac Allograft Rejection and Atherosclerosis
Grattan, M. T. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420240075030 · Cited by 968
Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis
Speir, E., Modali, R., Huang, E.-S., Leon, M. B., Shawl, F., Finkel, T., & Epstein, S. E. (1994) · Science · doi:10.1126/science.8023160 · Cited by 753
Regulation of differentiated properties and proliferation of arterial smooth muscle cells.
Thyberg, J., Hedin, U., Sjölund, M., Palmberg, L., & Bottger, B. A. (1990) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.10.6.966 · Cited by 553
Gao, S.-Z., Alderman, E. L., Schroeder, J. S., Silverman, J. F., & Hunt, S. A. (1988) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(88)90402-0 · Cited by 499
Self-citationZhou, Y. F., Leon, M. B., Waclawiw, M. A., Popma, J. J., Yu, Z. X., Finkel, T., & Epstein, S. E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350903 · Cited by 451
A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation
Merigan, T. C., Renlund, D. G., Keay, S., Bristow, M. R., Starnes, V., O'Connell, J. B., Resta, S., Dunn, D., Gamberg, P., Ratkovec, R. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204303261803 · Cited by 376
Self-citationMcDonald, K., Rector, T. S., Braunlin, E. A., Kubo, S. H., & Olivari, M. T. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90535-3 · Cited by 316
Loebe, M., Schüler, S., Zais, O., et al. (1991) · PubMed · Cited by 116
Lemström, K., Koskinen, P., Krogerus, L. A., Daemen, M. J. A. P., Bruggeman, C. A., & Häyry, P. (1995) · Circulation · doi:10.1161/01.cir.92.9.2594 · Cited by 108
Cited by
Infection in Solid-Organ Transplant Recipients
Fishman, J. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra064928 · Cited by 1,950
Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients
Ljungman, P., Griffiths, P., & Paya, C. (2002) · Clinical Infectious Diseases · doi:10.1086/339329 · Cited by 1,234
Kavey, R.-E. W., Allada, V., Daniels, S. R., Hayman, L. L., McCrindle, B. W., Newburger, J. W., Parekh, R. S., & Steinberger, J. (2006) · Circulation · doi:10.1161/circulationaha.106.179568 · Cited by 707
Pathogenesis of human cytomegalovirus in the immunocompromised host
Griffiths, P., & Reeves, M. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00582-z · Cited by 610
Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients
(2008) · JAMA · doi:10.1001/jama.300.4.413 · Cited by 572
Metadata
- Authors
- Valantine, H. A., Gao, S.-Z., Menon, S. G., Renlund, D. G., Hunt, S. A., Oyer, P., Stinson, E. B., Brown, B. W., Merigan, T. C., & Schroeder, J. S.
- Venue
- Circulation
- Published
- 1999-07-06
- Volume
- 100
- Issue
- 1
- Pages
- 61-66
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1979037054
- Cited by
- 292
- References
- 12
- FWCI
- 18.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Prophylactic Immediate Posttransplant Ganciclovir on Development of Transplant Atherosclerosis: A Post Hoc Analysis of a Randomized, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1161/01.cir.100.1.61
- The paper
- Valantine, H. A., Gao, S.-Z., Menon, S. G., Renlund, D. G., Hunt, S. A., Oyer, P., Stinson, E. B., Brown, B. W., Merigan, T. C., & Schroeder, J. S. (1999). Impact of Prophylactic Immediate Posttransplant Ganciclovir on Development of Transplant Atherosclerosis: A Post Hoc Analysis of a Randomized, Placebo-Controlled Study. Circulation. https://doi.org/10.1161/01.cir.100.1.61
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.